Blood Glucose Determinations Differ in Plasma and Serum
|
By LabMedica International staff writers Posted on 05 Jul 2012 |
|
Blood glucose determination is one of the most common clinical diagnostic tests and accurate and precise measurement of blood glucose is of great importance in the diagnosis and management of diabetes.
The concentration of glucose in the blood will continue to decrease over time after phlebotomy because of glycolysis, which will occur in erythrocytes, white blood cells (WBCs), and platelets as these cells can continue to metabolize glucose.
Laboratory scientists at the University of Mysore, (Manasagangotri, India) investigated the effect of time and the method of processing of blood on the blood glucose levels. Blood from 30 different patients who came for routine blood glucose determination were used in the study. Whole blood was divided into three portions. One portion was allowed to clot. To the second portion, 2mg/mL sodium fluoride was added, and to the third portion, ethylene diamine tetra acetic acid (EDTA)–disodium salt was added.
Blood sugar was estimated using a blood sugar assay kit (Becton Dickinson, Bangalore, India). Optical Density (OD) of the colored complex was measured at 620 nm in an autoanalyzer. Blood sugar in these samples stored at room temperature was measured again after four hours and eight hours. The serum gave values lower than fluoride plasma by 1.15%. Although this difference was statistically significant, it may not be physiologically relevant. On storing the sample at room temperature for eight hours, the serum glucose value decreased by 8% and even fluoride plasma had 4.3% lower glucose.
The authors concluded that blood glucose should be determined within as short a time as possible after drawing the blood. The blood glucose values ranged from 76 to 410 mg/dL covering a wide range of blood glucose values that would be seen in any sample analysis. Serum may be a better sample for blood glucose determination particularly when there is a time delay in the measurement. If appropriate correction is applied, it may actually be a better sample than plasma. Moreover, many clinical analysis procedures require serum rather than plasma and therefore one single drawing of blood may suffice for even blood glucose estimation. The study was published online on May 14, 2012, in the Journal of Clinical Laboratory Analysis.
Related Links:
University of Mysore
Becton Dickinson
The concentration of glucose in the blood will continue to decrease over time after phlebotomy because of glycolysis, which will occur in erythrocytes, white blood cells (WBCs), and platelets as these cells can continue to metabolize glucose.
Laboratory scientists at the University of Mysore, (Manasagangotri, India) investigated the effect of time and the method of processing of blood on the blood glucose levels. Blood from 30 different patients who came for routine blood glucose determination were used in the study. Whole blood was divided into three portions. One portion was allowed to clot. To the second portion, 2mg/mL sodium fluoride was added, and to the third portion, ethylene diamine tetra acetic acid (EDTA)–disodium salt was added.
Blood sugar was estimated using a blood sugar assay kit (Becton Dickinson, Bangalore, India). Optical Density (OD) of the colored complex was measured at 620 nm in an autoanalyzer. Blood sugar in these samples stored at room temperature was measured again after four hours and eight hours. The serum gave values lower than fluoride plasma by 1.15%. Although this difference was statistically significant, it may not be physiologically relevant. On storing the sample at room temperature for eight hours, the serum glucose value decreased by 8% and even fluoride plasma had 4.3% lower glucose.
The authors concluded that blood glucose should be determined within as short a time as possible after drawing the blood. The blood glucose values ranged from 76 to 410 mg/dL covering a wide range of blood glucose values that would be seen in any sample analysis. Serum may be a better sample for blood glucose determination particularly when there is a time delay in the measurement. If appropriate correction is applied, it may actually be a better sample than plasma. Moreover, many clinical analysis procedures require serum rather than plasma and therefore one single drawing of blood may suffice for even blood glucose estimation. The study was published online on May 14, 2012, in the Journal of Clinical Laboratory Analysis.
Related Links:
University of Mysore
Becton Dickinson
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Electrolyte Analyzer
CBS-4000 (CBS-400)
Automated Clinical Chemistry Analyzer
Envoy 500+
Latest Clinical Chem. News
- Common HbA1c Assay May Miss Diabetes in People with Sickle Cell Trait
- Blood Protein Panel Predicts Timing of ALS Symptom Onset
- Siemens Adds CE-Marked Capillary Claims for 24 Assays on Atellica Analyzers
- Preoperative Blood Test Predicts Colorectal Cancer Recurrence and Metastasis
- New Machine-Learning Equation Improves LDL Cholesterol Assessment
- Ultrasensitive Biosensor Detects Early Liver Fibrosis from Blood
- Blood Biomarker May Signal Cognitive Decline Risk a Decade Before Symptoms
- Blood Test Improves Alzheimer’s Diagnosis Across Care Settings
- New Immunoassay Enables Ultrasensitive Blood-Based Tau Tangle Measurement
- Blood Hormone Pattern Distinguishes Endometriosis with High Accuracy
- Blood Test Brings Alzheimer’s Biomarker Assessment to Routine Labs
- Alzheimer’s Biomarkers Identify Faster Cognitive Decline in Adults Over 80
- ADLM Issues Laboratory Guidance for Gender-Diverse Patient Care
- FDA-Approved Test Identifies Low Risk of Large Esophageal Varices in Cirrhosis
- Blood Protein Signature Diagnoses Pediatric IBD and Distinguishes Subtypes
- Blood Test Detects More High-Risk Prostate Cancers Than PSA
Channels
Molecular Diagnostics
view channel
AI Tool Improves Long-Read Detection of Cancer Mutations
Accurate identification of somatic mutations remains difficult, particularly in structurally complex genomic regions. Short-read sequencing pipelines can miss clinically relevant variants, limiting research... Read more
FDA Clears Molecular Test for Bacterial Vaginosis and Candida Vaginitis
Vaginitis is a common reason for clinical visits, with bacterial vaginosis and Candida vaginitis among the leading causes. Overlapping symptoms and reliance on microscopy, pH testing, and clinical observation... Read more
Hematology
view channel
Spectral Flow Cytometry Assay Enhances MRD Detection in Multiple Myeloma
Minimal residual disease (MRD) monitoring is pivotal in multiple myeloma, where persistent malignant plasma cells drive relapse risk and help guide therapy decisions. In the United States, approximately... Read more
New Marker Helps Detect Aggressive Multiple Myeloma Earlier
Multiple myeloma is an incurable malignancy of plasma cells and the second most common blood cancer worldwide, with more than 188,000 new cases each year. Although therapies have advanced, most patients... Read more
Immunology
view channel
Study Reveals Immune Mechanism Driving Severe COVID-19 Progression
Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more
Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis
Inflammatory bowel disease often develops after a prolonged symptom-free period, complicating timely recognition and clinical intervention. Limited understanding of immune activity during this silent phase... Read more
Ultrasensitive Blood Test Detects Sjögren’s Signature Years Before Diagnosis
Sjögren’s disease is a common autoimmune condition that can be difficult to recognize early, leading to delayed diagnosis and persistent symptom burden. It affects around half a million people in the UK... Read more
New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients
Eurofins Viracor has introduced three plasma-based assays—CXCL9 (Test Code 33607), CXCL10 (Test Code 33609), and interleukin-18 (IL-18) (Test Code 33611)—expanding its immunology testing menu for transplant... Read moreMicrobiology
view channel
New Sensitive Blood Assay Detects Tuberculosis Antigen Directly in Blood
Tuberculosis continues to be a leading global infectious disease, and diagnosis still hinges on sputum samples that many patients cannot produce early in illness. Delays in confirming Mycobacterium tuberculosis... Read more
High-Throughput Automated Platform to Advance Latent Tuberculosis Testing
Testing for tuberculosis remains a persistent global need, with demand driven by immigration screening, pre-treatment evaluation for immunosuppressive therapies, and public health programs.... Read more
Pathology
view channel
AI Pathology Tool Stratifies Rectal Cancer to Guide Chemoradiotherapy
Choosing intensified regimens for locally advanced rectal cancer is challenging because these therapies can cause serious side effects. Colorectal cancer is the fourth-most fatal cancer in the UK, and... Read more
PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers
Agilent Technologies’ PD-L1 IHC 22C3 pharmDx (Code SK006) has received European Union certification as a companion diagnostic to aid in identifying patients with epithelial ovarian, fallopian tube, or... Read more
Technology
view channel
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read more
Industry
view channel
LumiQuick Advances Oxidative Stress Research with Expanded AOXRE Portfolio
LumiQuick Diagnostics, Inc. (Santa Clara, CA, USA) has announced the addition of the AOXRE product line to its portfolio and introduced expanded services to help biotechnology and diagnostic companies... Read more
Collaboration Advances Sputum-Based Diagnostics for Asthma and COPD
Asthma and chronic obstructive pulmonary disease are highly prevalent inflammatory airway conditions, affecting more than 40 million Americans and more than 650 million people worldwide.... Read more
